Analytic Investors’s TherapeuticsMD TXMD Stock Holding History

Analytic Investors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-586	Closed	-$249K	–	686
2016 Q2	$249K	Buy	+586	New	+$241K	﹤0.01%	557
2016 Q1	–	Sell	-2,866	Closed	-$1.49M	–	688
2015 Q4	$1.49M	Buy	2,866 +648	+29%	+$239K	0.02%	335
2015 Q3	$650K	Buy	+2,218	New	+$788K	0.01%	422

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Analytic Investors's TXMD Position: Q3 2016 in Review

Analytic Investors sold out of TherapeuticsMD (TXMD) in Q3 2016, closing a stake of 586 shares — an estimated $249K sold.

Analytic Investors first reported a position in TXMD in Q3 2015 and held it in 3 quarters. The position peaked at $1.49M in Q4 2015. 137 funds tracked by Wall St. Rank hold TXMD as of Q3 2016.

Analytic Investors reported no remaining TherapeuticsMD position as of Q3 2016 after selling out during the quarter.
Analytic Investors sold 586 TherapeuticsMD shares in Q3 2016, an estimated $249K.
Analytic Investors first reported a position in TherapeuticsMD in Q3 2015 and held it in 3 quarters.
Analytic Investors's TherapeuticsMD position peaked at $1.49M in Q4 2015.
137 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.